Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 20/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.40 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.40 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27233713 | 1.00 | TIPARP (0.47) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL24968387 | 0.92 | TIPARP (0.47) | TIPARP | |
| SCHEMBL24968935 | 0.85 | TIPARP (0.54) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL27233815 | 0.85 | TIPARP (0.54) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL24968339 | 0.85 | TIPARP (0.54) | TIPARPPARP1CYP2C9PARP14PARP16 | |
| SCHEMBL24968216 | 0.82 | TIPARP (0.45) | TIPARP | |
| SCHEMBL24968338 | 0.81 | PIK3CD (0.35) | — | |
| SCHEMBL27233855 | 0.81 | PIK3CD (0.35) | — | |
| SCHEMBL24968934 | 0.81 | PIK3CD (0.35) | — | |
| SCHEMBL24968342 | 0.81 | HCRTR1 (0.36) | TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |